Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy (Q38617375)

4 September 2017

title

Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy (English)

1 reference

4 September 2017

1 reference

Flavia Stella

1

1 reference

4 September 2017

Estela Pedrazzini

2

1 reference

4 September 2017

Mara Agazzoni

3

1 reference

4 September 2017

Oscar Ballester

4

1 reference

4 September 2017

Irma Slavutsky

5

1 reference

4 September 2017

publication date

27 October 2015

1 reference

4 September 2017

1 reference

4 September 2017

volume

33

1 reference

4 September 2017

issue

10

1 reference

4 September 2017

page(s)

496-504

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

4 September 2017

1 reference

IMWG consensus on risk stratification in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Molecular pathogenesis of multiple myeloma and its premalignant precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Multiple myeloma: evolving genetic events and host interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Chromosome translocations in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

The prognostic significance of cytogenetics and molecular profiling in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Clinical and biologic implications of recurrent genomic aberrations in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Expression of cyclin-dependent kinase subunit 1 (Cks1) is regulated during the cell cycle by a CDE/CHR tandem element and is downregulated by p53 but not by p63 or p73.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Genetic aberrations and survival in plasma cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transpla

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

New Recurrent Chromosome Alterations in Patients with Multiple Myeloma and Plasma Cell Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Genetic events in the pathogenesis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Cell cycle: reaching for a role for the Cks proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

The SCF ubiquitin ligase: insights into a molecular machine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Deletions of CDKN2C in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Molecular pathogenesis and a consequent classification of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

The (11;14)(q13;q32) Translocation in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/07357907.2015.1080833

10.3109/07357907.2015.1080833

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference